Hypertension is one of the common untreated diseases and poses major risk for heart failure, renal failure, cerebrovascular disease, cardiovascular disease, and coronary heart disease.
Global Resistant Hypertension Treatment Market: Overview
Hypertension is one of the common untreated diseases and poses major risk for heart failure, renal failure, cerebrovascular disease, cardiovascular disease, and coronary heart disease. About less than half of hypertensive patients in the U.S. are using economical generic antihypertensive drugs (AHDs). About 5%-10% (maximum to 20%-30%) of hypertensive patients with incompetently controlled hypertension have resistant hypertension.
Read Report Overview - https://www.transparencymarketresearch.com/resistant-hypertension-treatment-market.html
Resistant hypertension is a condition when the blood pressure remains higher than the normal range despite optimum dosage of three antihypertensive drugs, including a diuretics. Resistant hypertension includes patients whose blood pressure controlled on ≥ 4 antihypertensive drugs, but excludes those with uncontrolled blood pressure on <3 antihypertensive drugs or suboptimal antihypertensive drugs regimen.
According to the latest research studies, prevalence rate of resistant hypertension is estimated to increase in the future. Resistant hypertension is found in patients with chronic kidney disease (CKD), left ventricular hypertrophy (LVH), diabetes, higher systolic BP, obesity, and also among elderly patients. Resistant hypertensive patients are at higher risk of serious cardiovascular outcomes, hospitalization, and heart stroke, in particular.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=41111
Global Resistant Hypertension Treatment Market: Drivers and Restraints
Resistant hypertension is different from uncontrolled hypertension. For a precise identification of prevalence of resistant hypertension, a compulsory titration study of a large and diverse hypertensive group is required. Resistant hypertension denotes a risky phenotype. Genetic factors play a more crucial role in resistant hypertension as compared to general hypertension. Although for resistant hypertensive patients, genetic valuations are limited. In one of the limited genetic assessments of patients in Finland, investigators screened 347 patients with resistant hypertension who had mutation on the γ and β subunits of the epithelial sodium channel.
Mutation on the γ and β subunits can cause Liddle’s syndrome. Liddle’s syndrome is a rare form of hypertension (monogenic). According to data collected by the National Health and Nutrition Examination Survey (NHANES) from its study of samples of non-institutionalized, adult, civilian population, the prevalence rate of resistant hypertension was estimated around 8.9?±?0.6% among the population of the U.S. during 2003 to 2008. The study suggests that resistant hypertension and hypertension have become wide-spread due to increase of obesity among the general population and growth in geriatric population.
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=41111
Resistant hypertension is more prevalent among the non-black Hispanic or African America, male, obese, and elderly population. The global resistant hypertension treatment market has been expanding over the years. Growth in geriatric population is a major factor boosting the resistant hypertension treatment market. Increase in consumption of alcohols, junk foods, etc. is another key driver of the resistant hypertension treatment market. However, ignorance and drug resistance are the main restraints of the resistant hypertension treatment market.
Global Resistant Hypertension Treatment Market: Key Segments
The global resistant hypertension treatment market can be segmented based on type of treatment, end-user, and region. In terms of type of treatment, the global resistant hypertension treatment market can be classified into diuretic therapy, combination therapy, mineralocorticoid receptor antagonists, and others. Based on end-user, the global resistant hypertension treatment market can be categorized into hospital pharmacy, retail pharmacy, and online pharmacy. In terms of region, the global resistant hypertension treatment market can be divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Pre Book Resistant Hypertension Treatment Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=41111<ype=S
North America is expected to dominate the global resistant hypertension treatment market due to availability of advanced medications in the region. Awareness regarding the disease is another factor boosting the resistant hypertension treatment market in North America. The resistant hypertension treatment market in Asia Pacific is anticipated to expand at a high growth rate due to increase in prevalence of the disease in the region. In Middle East & Africa, owing to unawareness about the disease in the underdeveloped countries such as Turkey, Cyprus, Syria, Lebanon, Iraq, etc. the resistant hypertension treatment market is expanding in the region.
Global Resistant Hypertension Treatment Market: Key Players
Key players operating in the global resistant hypertension treatment market are Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Sanofi, F. Hoffmann-La Roche Ltd., and Amgen Inc., among others.
Browse more Reports by Transparency Market Research:
Meningococcal Infections Treatment Market: https://www.transparencymarketresearch.com/meningococcal-infections-treatment-market.html
Cardiac MRI Testing Market: https://www.transparencymarketresearch.com/cardiac-mri-testing-market.html
Oral Drug Delivery Systems Market: https://www.transparencymarketresearch.com/oral-drug-delivery-systems-market.html
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/